Lung metastasectomy is an accepted treatment for selected patients with pulmonary metastases. Resectability, disease-free interval and number of metastases are well characterised prognostic indicators after lung metastasectomy. Patients treated with lung metastasectomy for epithelial tumours were retrospectively reviewed. One hundred and forty-two patients were reviewed. The rate of mediastinal node metastases was 12\%. Overall 5-year survival rate was 36\% with a median survival time of 47 months. Recurrence rate after lung metastasectomy was 50\%. Five-year disease-free survival was 26\% with a median of 29 months. Mediastinal nodal status negatively affected survival at univariate analysis (5-years 32\% for N+ and 40\% for N-, P=0.013). Disease-free survival was significantly different according to nodal status: 5-year disease-free survival 17 and 28\% for N+ and N-, respectively (P=0.053). Systemic recurrences were more frequent in patients with nodal involvement (P=0.058). Mediastinal nodal involvement resulted in a significant prognostic factor at multivariate analysis (N+: RRD=3.0; 95\% CI 1.3-6.7). Patients with pulmonary metastases and nodal involvement had a poor prognosis and relapsed early after pulmonary metastasectomy. Nodal status should be considered in the selection of patients for lung metastasectomy.
|Data di pubblicazione:||2006|
|Titolo:||Prognostic factors and survival after resection of lung metastases from epithelial tumours.|
|Autori:||C., Casali; Stefani, Alessandro; E., Storelli; Morandi, Uliano|
|Digital Object Identifier (DOI):||10.1510/icvts.2005.125856|
|Appare nelle tipologie:||Articolo su rivista|
File in questo prodotto:
|Prognostic factors and survival after resection of lung metastases from epithelial tumors.pdf||articolo principale||Versione editoriale||Administrator Richiedi una copia|
I documenti presenti in Iris Unimore sono rilasciati con licenza Creative Commons Attribuzione - Non commerciale - Non opere derivate 3.0 Italia, salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris